세계 항체 의약품 시장 규모는 2024년 2,426억 달러에서 예측 기간 동안 11.2%의 CAGR을 기록하며 2029년 말에는 4,121억 달러 규모에 이를 것으로 예상됩니다.
북미는 2024년 1,322억 달러에서 연평균 10.3% 성장하여 2029년 말에는 2,159억 달러에 달할 것으로 예상됩니다. 유럽 지역은 2024년 716억 달러에서 연평균 12.1% 성장하여 2029년 말에는 1,269억 달러에 달할 것으로 예상됩니다.
세계 항체 의약품 시장을 조사했으며, 시장 개요, 시장 영향요인 및 시장 기회 분석, 규제 환경, 신흥 기술 및 기술개발 동향, 시장 규모 추정 및 예측, 각 부문별·지역별 상세 분석, 경쟁 상황, 주요 기업 프로파일 등의 정보를 정리하여 전해드립니다.
목차
제1장 주요 요약
시장 전망
조사 범위
시장 분석
제2장 시장 개요
항체와 항원
항체 기능
단클론항체
단클론항체의 역사
단클론항체 : 장단점
단클론항체 종류
단클론항체 제조 기술
단클론항체 용도
제3장 시장 역학
성장 촉진요인
암과 자가면역질환 발생률 증가
신제품 발매
성장 억제요인
고가격과 가격 압력
mAbs의 부작용과 한계
기회
라이선싱 및 협업 계약
제조의 진보와 제품 수율 향상
제4장 규제 측면
규제 시나리오
가격통제
단클론항체의 새로운 승인
제5장 신기술과 개발
개요
신기술
이중특이성항체와 다중특이성항체
항체약물접합체
항체 융합 단백질
항체 의약품 공학의 AI와 ML
제6장 시장 세분화 분석
세분화 내역
세계의 항체 의약품 시장 : 항체 유형별
인간 단클론항체
인간화 단클론항체
키메라 단클론항체
마우스 단클론항체
세계의 항체 의약품 시장 : 제조 공정별
포유류 세포배양
미생물 세포 발효
세계의 항체 의약품 시장 : 용도별
자가면역질환
고형 종양
림프종, 백혈병, 다발성 골수종
기타
지역적 내역
세계의 항체 의약품 시장 : 지역별
시장 규모와 예측
북미
유럽
아시아태평양
기타 지역
제7장 경쟁 정보
경쟁 상황
인간 단클론항체 시장 점유율
인간화 단클론항체 시장 점유율
키메라 단클론항체 시장 점유율
제8장 새로운 개발과 임상시험 활동
새로운 전개와 M&A 분석
임상시험 활동
제I상 임상시험
제II상 임상시험
제III상 임상시험
제IV상 임상시험
제9장 지속가능성 : 항체 의약품 시장의 ESG 관점
항체 의약품 시장의 지속가능성
ESG 데이터 이해
환경 퍼포먼스
사회적 퍼포먼스
거버넌스 퍼포먼스
BCC에 의한 결론
제10장 부록
조사 방법
정보 출처
두문자어
기업 개요
ABBVIE INC.
AMGEN INC.
ASTRAZENECA
BRISTOL-MYERS SQUIBB CO.
F. HOFFMANN-LA ROCHE LTD.
JOHNSON & JOHNSON SERVICES INC.
LILLY
MERCK KGAA
NOVARTIS AG
PFIZER INC.
REGENERON PHARMACEUTICALS INC.
SANOFI
ksm
영문 목차
영문목차
The global market for antibody drugs is expected to grow from $242.6 billion in 2024 and is projected to reach $412.1 billion by the end of 2029, at a compound annual growth rate (CAGR) of 11.2% during the forecast period of 2024 to 2029.
The North American market for antibody drugs is expected to grow from $132.2 billion in 2024 and is projected to reach $215.9 billion by the end of 2029, at a CAGR of 10.3% during the forecast period of 2024 to 2029.
The European market for antibody drugs is expected to grow from $71.6 billion in 2024 and is projected to reach $126.9 billion by the end of 2029, at a CAGR of 12.1% during the forecast period of 2024 to 2029.
Report Scope
This study offers a global view of the antibody drugs that have become key components of the pharmaceutical and biopharmaceutical markets. It analyzes and assesses therapeutic applications of monoclonal antibodies (mAbs) in human medicine, including the combination of mAbs when attached to cytotoxic agents such as antibody drug conjugates (ADCs).
BCC Research analyzed and made projections of each market and its applications, along with an analysis of the regulatory environment, new products and technological advances. Also included in the report are profiles of leading companies in the antibody drug industry, such as AbbVie Inc., Amgen Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., and Merck KGaA.
Monoclonal antibodies are finding growing use in the treatment of chronic diseases. This report focuses on the global market for antibody drug products and provides an updated review of their applications in various disease sectors. The overall market for antibody drug products includes four primary areas of applications: autoimmune diseases; solid tumors; lymphoma and leukemia; and other diseases such as asthma, osteoporosis and cardiovascular diseases.
This report excludes polyclonal antibodies, screening kits and diagnostic uses of mAbs. It also excludes the research applications of mAbs and therapeutic antibodies for veterinary use. The report excludes antibody products for COVID-19 and vaccine-based products.
The market is segmented by geographical region: North America, Europe, Asia-Pacific, and the Rest of the World (RoW). Regional analysis is further broken down by country as follows: North America-the U.S., Canada and Mexico; Europe-Germany, the U.K., France, Italy, Spain, and the Rest of Europe; Asia-Pacific-China, Japan, India, South Korea, Australia, and the Rest of Asia-Pacific. For market estimates, data has been provided for 2021 and 2022 as the historic years, 2023 as the base year, and forecasts through 2029.
Report Includes
76 data tables and 55 additional tables
An updated review of the global market for antibody drugs
Analyses of the global market trends, with data from 2021-2023, estimates for 2024, and projections of compound annual growth rates (CAGRs) through 2029
Evaluation of the overall market for antibody drugs, and corresponding market share analysis by type, manufacturing process, application, and region
Description of antibody functions and how they compare with antigens, and a discussion of monoclonal antibodies (mAbs), including their history, advantages and disadvantages, types, manufacturing technologies and applications
Coverage of new approvals, recalls, safety alerts and clinical trials of mAbs, as well as technical issues related to human anti-mouse antibody (HAMA), and factors affecting mAB drugs
An assessment of the major technologies for the formulation of antibody drugs and their relation to biotechnology, immunology, pharmaceuticals, and biodefense companies
Discussions of the market dynamics, opportunities and challenges, as well as emerging technologies
Overview of the sustainability trends and ESG developments in the industry, with emphasis on the ESG practices followed by leading companies, their ESG ratings, and consumer attitudes
Competitive intelligence, including companies' market shares, recent M&A activity and venture funding
Profiles of the leading companies, including F. Hoffmann-La Roche Ltd., Johnson & Johnson Services Inc., AbbVie Inc., Merck KGaA, and Amgen Inc.
Table of Contents
Chapter 1 Executive Summary
Market Outlook
Scope of Report
Market Insights
Chapter 2 Market Overview
Antibodies and Antigens
Antibody Functions
Monoclonal Antibodies
History of Monoclonal Antibodies
Monoclonal Antibodies: Advantages and Disadvantages
Types of Monoclonal Antibodies
Manufacturing Technologies of Monoclonal Antibodies
Applications of Monoclonal Antibodies
Chapter 3 Market Dynamics
Drivers
Increasing Incidence of Cancer and Autoimmune Diseases
New Product Launches
Restraints
High Prices and Pricing Pressure
Side Effects and Limitations of mAbs
Opportunities
Licensing and Collaboration Agreements
Manufacturing Advances and Improving Product Yields
Chapter 4 Regulatory Aspects
Regulatory Scenario
Price Controls
New Approvals of Monoclonal Antibodies
Chapter 5 Emerging Technologies and Developments
Overview
Emerging Technologies
Bispecific Antibodies and Multi-Specific Antibodies
Antibody-Drug Conjugates
Antibody Fusion Proteins
AI and ML in Antibody Drug Engineering
Chapter 6 Market Segmentation Analysis
Segmentation Breakdown
Global Market for Antibody Drugs, by Antibody Type
Human Monoclonal Antibodies
Humanized Monoclonal Antibodies
Chimeric Monoclonal Antibodies
Murine Monoclonal Antibodies
Global Market for Antibody Drugs, by Manufacturing Process
Mammalian Cell Culture
Microbial Cell Fermentation
Global Market for Antibody Drugs, by Application
Market by Application
Autoimmune Diseases
Solid Tumors
Lymphoma, Leukemia and Multiple Myeloma
Others
Geographic Breakdown
Global Market for Antibody Drugs, by Region
Market Size and Forecast
North America
Europe
Asia-Pacific
Rest of the World (RoW)
Chapter 7 Competitive Intelligence
Competitive Landscape
Market Share for Human Monoclonal Antibodies
Market Share for Humanized Monoclonal Antibodies
Market Share for Chimeric Monoclonal Antibodies
Chapter 8 New Developments and Clinical Trial Activities
New Developments and M&A Analysis
Clinical Trial Activities
Phase I Clinical Trials
Phase II Clinical Trials
Phase III Clinical Trials
Phase IV Clinical Trials
Chapter 9 Sustainability: An ESG Perspective in the Antibody Drugs Market
